Gain Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statement of Cash Flows
Consolidated Statement of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · 2023 · 2022 | ||||||
| · · · · | ||||||
| Operating activities: · · | ||||||
| Net loss | | $(22,267,520) | | $(17,590,738) | ||
| | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Depreciation and amortization | | 83,579 | | 64,168 | ||
| Stock based compensation expense | | 3,259,026 | | 1,526,434 | ||
| Other non cash items | | | (383,188) | | | (206,861) |
| | | | | | | |
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other currents assets | | | 184,446 | | | (114,005) |
| VAT credits | | | (130,068) | | | 3,631 |
| Long term deposit and other non current assets | | (10,057) | | (2,901) | ||
| Accounts payable | | (643,164) | | 1,066,707 | ||
| Other current liabilities | | | (50,534) | | | 711,073 |
| Defined benefit pension plan | | | 6,313 | | | 58,696 |
| Deferred income | | 1,085,294 | | (208,343) | ||
| Total changes in operating assets and liabilities | | 442,230 | | 1,514,858 | ||
| Net cash used in operating activities | | | (18,865,873) | | | (14,692,139) |
| | | | | | | |
| Cash flows from investing activities: | | | | |||
| Purchase of property and equipment and internal-use of software | | (15,358) | | (118,953) | ||
| Purchases of marketable securities | | | (1,956,350) | | | (17,735,355) |
| Maturities of marketable securities | | | 12,194,375 | | | 3,079,495 |
| Net cash provided/(used) by/in investing activities | | | 10,222,667 | | | (14,774,813) |
| | | | | | | |
| Cash flow from financing activities: | | | | |||
| Net proceeds from issuance of shares in at-the-market (ATM) offering | | 3,544,876 | | — | ||
| Net proceeds from issuance of shares and warrants in public offering and private placement | | 9,185,534 | | — | ||
| Payments of current portion of long-term debt | | | (89,067) | | | (78,774) |
| Net cash provided/(used) by/in financing activities | | $12,641,343 | | $(78,774) | ||
| Effect of exchange rate changes | | 488,404 | | (23,797) | ||
| Net increase / (decrease) in cash, cash equivalents and restricted cash | | $4,486,541 | | $(29,569,523) | ||
| Cash, cash equivalents and restricted cash at beginning of period | | 7,342,429 | | 36,911,952 | ||
| Cash, cash equivalents and restricted cash at end of period | | $11,828,970 | | $7,342,429 | ||
| | | | | | | |
| Supplemental Data: | | | | | | |
| Income taxes paid | | | 134,962 | | | 2,740 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.